# A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

> **NCT06679101** · PHASE3 · RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 520 (estimated)

## Conditions studied

- Multiple Myeloma
- Newly Diagnosed Multiple Myeloma

## Interventions

- **DRUG:** Belantamab mafodotin
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone
- **DRUG:** Daratumumab

## Key facts

- **NCT ID:** NCT06679101
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-16
- **Primary completion:** 2031-04-28
- **Final completion:** 2031-04-28
- **Target enrollment:** 520 (ESTIMATED)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06679101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06679101, "A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06679101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*